Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

Axel Heidenreich, Patrick J. Bastian, Joaquim Bellmunt et al. · European Urology · 2013 · 1.9K citations

Urology, Surgical Oncology, Genitourinary Cancer +6

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

Ali Afshar‐Oromieh, Eleni Avtzi, Frederik L. Giesel et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 966 citations · Full text

Prospective Comparison of ¹⁸ F-Fluoromethylcholine Versus ⁶⁸ Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

Joshua James Morigi, Phillip D. Stricker, Pim J. van Leeuwen et al. · Journal of Nuclear Medicine · 2015 · 560 citations · Full text

Value of ⁶⁸Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy

Isabel Rauscher, Tobias Maurer, Ambros J. Beer et al. · Journal of Nuclear Medicine · 2016 · 228 citations · Full text

Comparison of DOTA and NODAGA as chelators for 64Cu-labeled immunoconjugates

Sukhen C. Ghosh, Kenneth L. Pinkston, Holly Robinson et al. · Nuclear Medicine and Biology · 2014 · 68 citations

Immunocytochemical Technique, Immunology, Tumor Immunity +9